Kermode Bio

Kermode Bio is a biotechnology company focused on developing next-generation gene therapy delivery systems that overcome the limitations of pre-existing immunity. The company's proprietary platform engineers "cloaked" adeno-associated virus (AAV) vectors designed to evade detection by the host immune system, specifically neutralizing antibodies. By enabling the treatment of patients with prior AAV exposure and allowing for potential repeat dosing, Kermode Bio aims to significantly expand the reach and efficacy of gene therapies. As a spin-off from the University of British Columbia, the company leverages advanced synthetic biology and high-throughput capsid engineering. Their technology addresses a critical bottleneck in the field, potentially transforming the treatment landscape for a wide range of genetic disorders.